UnitedHealth Q3: Margin Recovery Continues but Growth Remains Elusive

What happened

UnitedHealth's Q3 2026 results showed continued margin improvement, as earnings surged and the medical cost ratio likely remained below the prior year, but the company again lost membership, with total lives served declining and utilization remaining elevated. The improvement mirrors the first half of 2026, where reported earnings were boosted by favorable prior-period reserve development, cost actions, and buybacks rather than organic volume growth. Revenue growth remained muted, and the company's Medicare Advantage enrollment continued to shrink, reflecting disciplined pricing and benefit design that sacrifices share for profitability. Optum Health volumes also remain under pressure, with people served and scripts filled still trending lower. The market is now weighing whether this margin-led recovery can translate into sustainable top-line growth, especially with commercial medical cost trends still above historical levels.

Implication

The Q3 report does not resolve the central debate from our prior work: margins are recovering, but membership and revenue are still contracting, which limits the upside for a stock trading at 26x earnings. Until management demonstrates that medical cost trends are normalizing without reserve releases and that Medicare Advantage enrollment stabilizes, the stock is unlikely to rerate meaningfully higher. Conversely, if underlying margins continue to improve and enrollment losses moderate, the current price could be supported by earnings resilience and buybacks. We maintain our WAIT rating, with an attractive entry below $365 and a trim level above $445; the current price near $410 offers no margin of safety. Monitor the 4Q26 earnings and the Annual Enrollment Period (AEP) results for signs that the franchise is returning to growth.

Thesis delta

The thesis remains unchanged: UnitedHealth is delivering margin recovery, but growth remains negative as membership continues to shrink. Q3 results reinforce the view that earnings quality is mixed, with improvements likely still supported by favorable reserve development and cost actions, while elevated utilization suggests underlying medical cost trends have not fully normalized. We see no reason to change our WAIT rating or valuation boundaries.